Clinical Edge Journal Scan

Fertility preservation safe in young women with BC


 

Key clinical point: Women who were diagnosed with breast cancer (BC) at a young age and underwent fertility preservation (FP) did not experience any increased risk for disease-specific mortality or relapse.

Major finding: Compared with women who did not undergo FP, disease-specific mortality was similar in women who underwent hormonal FP (adjusted hazard ratio [aHR] 0.59; 95% CI 0.32-1.09) and nonhormonal FP (aHR 0.51; 95% CI 0.20-1.29). Hormonal (aHR 0.81; 95% CI 0.49-1.37) and nonhormonal (aHR 0.75; 95% CI 0.35-1.62) FP were associated with similar relapse or death rates in a subcohort of 723 women with complete relapse information.

Study details : Findings are from an analysis of a population-based nationwide cohort study including 1275 women of reproductive age (18-44 years old) who were diagnosed with BC, of which 425 women received hormonal (n = 367) or nonhormonal (n = 58) FP treatment.

Disclosures: This study was supported by the Swedish Cancer Society and other sources. Prof. Bergh declared receiving grants and personal fees from several sources.

Source: Marklund A et al. Relapse rates and disease-specific mortality following procedures for fertility preservation at time of breast cancer diagnosis. JAMA Oncol. 2022 (Aug 25). Doi: 10.1001/jamaoncol.2022.3677

Recommended Reading

Sex is still a taboo subject for patients with breast cancer
MDedge Hematology and Oncology
FDA warns of cancer risk in scar tissue around breast implants
MDedge Hematology and Oncology
Time to cancer diagnoses in U.S. averages 5 months
MDedge Hematology and Oncology
De-escalation of locoregional radiotherapy after primary chemotherapy appears safe in cT1-2N1 BC
MDedge Hematology and Oncology
Sacituzumab govitecan bests chemotherapy in HR+/HER2− advanced BC
MDedge Hematology and Oncology
Early TNBC: Durvalumab+NACT improves survival despite modest pCR increase
MDedge Hematology and Oncology
Neratinib alone or in combination with capecitabine beneficial for advanced HER2+ BC
MDedge Hematology and Oncology
Reassuring survival outcomes with trastuzumab+lapatinib in small and node-negative HER2+ BC
MDedge Hematology and Oncology
Risk for brain metastasis highest with ERBB2+ and triple-negative metastatic BC
MDedge Hematology and Oncology
ER+/HER2+ BC: HER2-enriched subtype predicts poor response to AI therapy
MDedge Hematology and Oncology